Premium
Update of fecal markers of inflammation in inflammatory bowel disease
Author(s) -
Judd Thomas A,
Day Andrew S,
Lemberg Daniel A,
Turner Dan,
Leach Steven T
Publication year - 2011
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2011.06846.x
Subject(s) - calprotectin , medicine , inflammatory bowel disease , ulcerative colitis , lactoferrin , feces , inflammatory bowel diseases , disease , inflammation , gastroenterology , immunology , biology , paleontology , genetics
The diagnosis, prognosis, and assessment of disease activity of inflammatory bowel disease (IBD) require investigating clinical, radiological, and histological criteria, as well as serum inflammatory markers. However, a range of fecal inflammatory markers now appears to have the potential to greatly assist in these processes. Calprotectin, a prominent neutrophil protein, was identified two decades ago as a potentially revolutionary marker for IBD. Following this discovery, numerous additional markers, including S100A12, lactoferrin, and M2‐pyruvate kinase, have also been suggested as novel markers of IBD. In the present study, we provide an up‐to‐date review of fecal markers of IBD, and further, provide a novel analysis of each of these fecal markers in severe ulcerative colitis and compare their expression pattern in contrast to calprotectin.